Computationally guided design and synthesis of pyrimidine-oxazole hybrids as novel antidiabetic agents: kinetic and

Shoaib Khan1, Tayyiaba Iqbal1, Rafaqt Hussain2

  • 1Department of Chemistry, Abbottabad University of Science and Technology, Abbottabad 22500, Pakistan.

Insights

Researchers developed novel pyrimidine-based oxazole derivatives to combat diabetes mellitus (DM). Analog 8 showed potent inhibition against alpha-amylase and alpha-glucosidase, indicating promising anti-diabetic activity with no toxicological effects.

Area of Science:

  • Medicinal Chemistry
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus (DM) is a chronic endocrine disease characterized by hyperglycemia.
  • Complications include cardiovascular diseases, neuropathy, nephropathy, and Alzheimer's disease.
  • Effective management requires novel therapeutic agents targeting key enzymes.

Purpose of the Study:

  • To design and synthesize novel pyrimidine-based oxazole derivatives.
  • To evaluate the anti-diabetic potential of these compounds.
  • To investigate their inhibitory effects on alpha-amylase and alpha-glucosidase.

Main Methods:

  • Synthesis of pyrimidine-based oxazole derivatives from 4-chloro-6-methylpyrimidin-2-amine.
  • Structural characterization using 1H-NMR, 13C-NMR, and HREI-MS.
  • In vitro enzyme inhibition assays against alpha-amylase and alpha-glucosidase, compared to acarbose.
  • Molecular docking, molecular dynamics (MD) simulations, and density functional theory (DFT) studies.
  • Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) analysis.

Main Results:

  • Synthesized ten novel pyrimidine-based oxazole derivatives.
  • Compounds demonstrated moderate to excellent inhibitory activity against alpha-amylase and alpha-glucosidase.
  • Analog 8 exhibited the highest potency with IC50 values of 5.20 ± 0.10 μM (alpha-amylase) and 5.70 ± 0.10 μM (alpha-glucosidase).
  • Molecular docking and MD simulations supported the enzyme inhibition mechanism.
  • ADMET analysis indicated no toxicological effects for the potent compounds.

Conclusions:

  • Novel pyrimidine-based oxazole derivatives show significant anti-diabetic potential.
  • Analog 8 is a highly promising candidate for further development as an anti-diabetic agent.
  • The study provides a foundation for the development of new therapeutic strategies for diabetes management.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
304
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
333
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Aryldiazonium Salts to Azo Dyes: Diazo Coupling01:11

Aryldiazonium Salts to Azo Dyes: Diazo Coupling

The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
3.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
263